{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:36:18Z","timestamp":1781624178681,"version":"3.54.5"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T00:00:00Z","timestamp":1661385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>It is arduous to determine clinical solutions for Andersen-Tawil syndrome (ATS) in patients intolerant of \u03b2-blocker. Here, we present the case of a 7-year-old boy with periodic paralysis and dysmorphic features who experienced syncope four times during exercise. His ECG revealed enlarged U waves and QU-prolongation associated with ATS-specific U wave patterns, frequent PVCs, and non-sustained bidirectional or polymorphic ventricular tachycardia. The genetic test showed a <jats:italic>de novo<\/jats:italic> missense R218W mutation of <jats:italic>KCNJ2<\/jats:italic>. With the diagnosis of ATS and intolerance of \u03b2-blocker, the patient was prescribed oral medications of mexiletine 450 mg\/day without severe adverse effects. The repeat ECG showed decreased PVC burden from 38 to 3% and absence of ventricular tachycardia. He remained symptom-free during over 2 years of outpatient follow-up. This case demonstrates a new anti-arrhythmic therapy with mexiletine for prevention of life-threatening cardiac events in patients with ATS who are intolerant of \u03b2-blocker treatment.<\/jats:p>","DOI":"10.3389\/fcvm.2022.992185","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T10:22:51Z","timestamp":1661422971000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: Mexiletine suppresses ventricular arrhythmias in Andersen-Tawil syndrome"],"prefix":"10.3389","volume":"9","author":[{"given":"Jing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/j.hrthm.2013.05.014","article-title":"HRS\/EHRA\/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013","volume":"10","author":"Priori","year":"2013","journal-title":"Heart Rhythm."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1161\/CIRCULATIONAHA.104.472498","article-title":"Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype","volume":"111","author":"Zhang","year":"2005","journal-title":"Circulation."},{"key":"B3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S0092-8674(01)00342-7","article-title":"Mutations in Kir21 cause the developmental and episodic electrical phenotypes of Andersen's syndrome","volume":"105","author":"Plaster","year":"2001","journal-title":"Cell."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/europace\/eux351","article-title":"Different responses to exercise between Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia","volume":"20","author":"Inoue","year":"2018","journal-title":"Europace"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2013.10.010","article-title":"Andersen-Tawil syndrome: clinical and molecular aspects","volume":"170","author":"Nguyen H","year":"2013","journal-title":"Int J Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.hrthm.2006.12.031","article-title":"Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome","volume":"4","author":"B\u00f6kenkamp","year":"2007","journal-title":"Heart Rhythm"},{"key":"B7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.hrthm.2014.12.009","article-title":"Efficacy and safety of flecainide for ventricular arrhythmias in patients with Andersen-Tawil syndrome with KCNJ2 mutations","volume":"12","author":"Miyamoto","year":"2015","journal-title":"Heart Rhythm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00424-017-2079-7","article-title":"Late sodium current associated cardiac electrophysiological and mechanical dysfunction","volume":"470","author":"Yu","year":"2018","journal-title":"Pflugers Arch"},{"key":"B9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.tcm.2015.05.006","article-title":"Late sodium current: a mechanism for angina, heart failure, and arrhythmia","volume":"26","author":"Makielski","year":"2016","journal-title":"Trends Cardiovasc Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1476-5381.1995.tb16342.x","article-title":"Mexiletine-induced shortening of the action potential duration of ventricular muscles by activation of ATP-sensitive K+ channels","volume":"115","author":"Sato","year":"1995","journal-title":"Br J Pharmacol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.992185\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T10:22:54Z","timestamp":1661422974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.992185\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":10,"alternative-id":["10.3389\/fcvm.2022.992185"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.992185","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"article-number":"992185"}}